DailyStocks Stock Article Search

https://www.boston.com/cars/national-news/2024/04/10/ford-recalls-nearly-43000-suvs-due-to-gas-leaks-that-can-cause-fires-but-remedy-wont-fix-leaks/ Apr 10, 2024 -

Ford is recalling nearly 43,000 small SUVs because gasoline can leak from the fuel injectors onto hot engine surfaces, increasing the risk of fires

The post Ford recalls nearly 43,000 SUVs due to gas leaks that can cause fires, but remedy won’t fix leaks appeared first on Boston.com.

0

https://www.zacks.com/stock/news/2253218/unveiling-m-t-bank-mtb-q1-outlook-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2253218 Apr 10, 2024 - Get a deeper insight into the potential performance of M&T Bank (MTB) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. 0

https://www.zacks.com/stock/news/2252179/bristol-myers-bmy-gets-fda-nod-for-label-expansion-of-abecma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252179 Apr 08, 2024 - Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma. 0

https://www.zacks.com/stock/news/2252143/will-t-rowe-trow-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2252143 Apr 08, 2024 - T. Rowe (TROW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. 0

https://www.zacks.com/stock/news/2251984/analysts-estimate-m-t-bank-corporation-mtb-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2251984 Apr 08, 2024 - M&T Bank (MTB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2251993/the-zacks-analyst-blog-highlights-t-mobile-us-abbott-laboratories-palo-alto-networks-enterprise-products-partners-and-the-pnc-financial-services?cid=CS-ZC-FT-press_releases-2251993 Apr 08, 2024 - T-Mobile US, Abbott Laboratories, Palo Alto Networks, Enterprise Products Partners and The PNC Financial Services are part of the Zacks top Analyst Blog. 0

https://seekingalpha.com/news/4087716-jj-wins-fda-nod-carvykti-label-expansion?source=feed_sector_healthcare Apr 06, 2024 - Johnson & Johnson (JNJ) has received FDA nod to expand the labeling for its CAR-T cell therapy Carvykti as an earlier line therapy for multiple myeloma. Read more here. 0

https://www.zacks.com/commentary/2251046/top-analyst-reports-for-t-mobile-us-abbott-laboratories-palo-alto-networks?cid=CS-ZC-FT-research_daily-2251046 Apr 05, 2024 - Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Palo Alto Networks, Inc. (PANW). 0

https://seekingalpha.com/news/4087599-piper-downgrades-achilles-to-neutral-cites-latest-data?source=feed_sector_healthcare Apr 05, 2024 - Piper Sandler has downgraded Achilles (ACHL) to neutral in the wake of Phase 1/2 data from its CHIRON and THETIS studies for its precision T cell therapy. Read more here. 0

https://seekingalpha.com/news/4087581-bristol-myers-2seventy-bio-receive-fda-approval-for-abecma-to-treat-multiple-myeloma?source=feed_sector_healthcare Apr 05, 2024 - The CAR T therapy Abecma has been approved for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy. Read more here. 0